Continuous evaluation of drug safety is needed following approval to determine adverse
events (AEs) in patient populations with diverse backgrounds. Spontaneous reporting …

Introduction Acne is a chronic, inflammatory, and immune mediated disease of
pilosebaceous unit, highly prevalent in adolescents. It involves face, trunk, and back; may …

Isotretinoin (13-cis-retinoic acid) is a non-aromatic retinoid that was approved by the United
States (US) Food and Drug Administration (FDA) as an oral capsule formulation in May 1982 …

Background Isotretinoin is a treatment option for severe nodulocystic acne. However, its use
has inconsistently been associated with the development of inflammatory bowel disease …

Introduction: Since it was introduced to the market by Hoffman-La Roche (Roche) in 1982,
isotretinoin has remained the most effective treatment for severe and recalcitrant acne …

Background Psychiatric adverse drug reactions (ADRs) are distressing for patients and have
important public health implications. We identified the drugs with the most frequent …

Background Drug‐induced gastrointestinal injury has been increasingly reported, but its
exact incidence is not known. The small and large intestines represent the most affected …

ABSTRACT Background & Aim: Incremental increase in the risk of serious infections with
combinations of tumor necrosis factor-alpha (TNF-α) inhibitors and immunomodulators …

Abstract Background & Aims: Reports have shown an increased risk of melanoma skin
cancer (MSC) with exposure to tumor necrosis factor alpha (TNF-α) inhibitors and non …

Background Transplacental transfer of tumour necrosis factor‐alpha (TNF‐α) inhibitors has
been shown in mothers receiving therapy for inflammatory bowel disease (IBD). Aim To …